title: High exposure to progesterone between the end of menstruation and the day of triggering final oocyte maturation is associated with a decreased probability of pregnancy in patients treated by in vitro fertilization and intracytoplasmic sperm injection.
abstract: OBJECTIVE
  To investigate the association between the probability of pregnancy and hormone exposure between the end of menstruation and the day of triggering final oocyte maturation (menstruation-free interval).
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  University.
  
  
  METHODS
  One hundred women (aged ≤ 39 years) stimulated with a fixed dose of recombinant follicle-stimulating hormone (200 IU).
  
  
  METHODS
  Daily gonadotropin-releasing hormone antagonist (GnRH, 0.25 mg) used from day 6 of stimulation onward, final oocyte maturation triggered by administration of 10,000 IU of human chorionic gonadotropin (hCG) as soon as ≥ 3 follicles ≥ 17 mm were present, and hormone assessment performed at initiation of stimulation, on the first day after menstruation had stopped, on the day of antagonist initiation, and on the day of hCG administration.
  
  
  METHODS
  The association between hormone exposure during the menstruation-free interval and the probability of ongoing pregnancy.
  
  
  RESULTS
  The exposure to progesterone during the menstruation-free interval was statistically significantly higher in patients who did not become pregnant compared with those who did (4.20 ± 2.54 vs. 3.13 ± 1.14, respectively). Binary logistic regression confirmed the adverse effect of the increased exposure to progesterone for the achievement of pregnancy.
  
  
  CONCLUSIONS
  In recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization/intracytoplasmic sperm injection cycles, a lower probability of pregnancy is associated with a higher exposure to progesterone during the menstruation-free interval.
authors.affiliation: Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium. mimikyrou@yahoo.gr
authors.forename: Dimitra
authors.initials: D
authors.lastname: Kyrou
authors.forename: Efstratios M
authors.initials: EM
authors.lastname: Kolibianakis
authors.forename: Human M
authors.initials: HM
authors.lastname: Fatemi
authors.forename: Michel
authors.initials: M
authors.lastname: Camus
authors.forename: Herman
authors.initials: H
authors.lastname: Tournaye
authors.forename: Basil C
authors.initials: BC
authors.lastname: Tarlatzis
authors.forename: Paul
authors.initials: P
authors.lastname: Devroey
mesh_terms: D000328:Adult; D005260:Female; D005307:Fertilization in Vitro / Q000639:trends*; D006801:Humans; D008598:Menstruation / Q000097:blood*; D009865:Oocytes / Q000254:growth & development / Q000378:metabolism*; D011247:Pregnancy; D018873:Pregnancy Rate / Q000639:trends*; D011374:Progesterone / Q000097:blood*; D011446:Prospective Studies; D020554:Sperm Injections, Intracytoplasmic / Q000639:trends*; D016896:Treatment Outcome
chemical_list: D011374:Progesterone